Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 38
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
BMC Infect Dis ; 24(1): 663, 2024 Jul 03.
Artículo en Inglés | MEDLINE | ID: mdl-38956476

RESUMEN

BACKGROUND: Severe COVID-19 is uncommon, restricted to 19% of the total population. In response to the first virus wave (alpha variant of SARS-CoV-2), we investigated whether a biomarker indicated severity of disease and, in particular, if variable expression of angiotensin converting enzyme 2 (ACE2) in blood might clarify this difference in risk and of post COVID -19 conditions (PCC). METHODS: The IRB-approved study compared patients hospitalized with severe COVID-19 to healthy controls. Severe infection was defined requiring oxygen or increased oxygen need from baseline at admission with positive COVID-19 PCR. A single blood sample was obtained from patients within a day of admission. ACE2 RNA expression in blood cells was measured by an RT-PCR assay. Plasma ACE1 and ACE2 enzyme activities were quantified by fluorescent peptides. Plasma TIMP-1, PIIINP and MMP-9 antigens were quantified by ELISA. Data were entered into REDCap and analyzed using STATA v 14 and GraphPad Prism v 10. RESULTS: Forty-eight patients and 72 healthy controls were recruited during the pandemic. ACE2 RNA expression in peripheral blood mononuclear cells (PBMC) was rarely detected acutely during severe COVID-19 but common in controls (OR for undetected ACE2: 12.4 [95% CI: 2.62-76.1]). ACE2 RNA expression in PBMC did not determine plasma ACE1 and ACE2 activity, suggesting alternative cell-signaling pathways. Markers of fibrosis (TIMP-1 and PIIINP) and vasculopathy (MMP-9) were additionally elevated. ACE2 RNA expression during severe COVID-19 often responded within hours to convalescent plasma. Analogous to oncogenesis, we speculate that potent, persistent, cryptic processes following COVID-19 (the renin-angiotensin system (RAS), fibrosis and vasculopathy) initiate or promote post-COVID-19 conditions (PCC) in susceptible individuals. CONCLUSIONS: This work elucidates biological and temporal plausibility for ACE2, TIMP1, PIIINP and MMP-9 in the pathogenesis of PCC. Intersection of these independent systems is uncommon and may in part explain the rarity of PCC.


Asunto(s)
Enzima Convertidora de Angiotensina 2 , COVID-19 , Leucocitos Mononucleares , SARS-CoV-2 , Humanos , COVID-19/sangre , Enzima Convertidora de Angiotensina 2/sangre , Enzima Convertidora de Angiotensina 2/genética , Enzima Convertidora de Angiotensina 2/metabolismo , Masculino , Femenino , Persona de Mediana Edad , Leucocitos Mononucleares/metabolismo , Leucocitos Mononucleares/virología , Anciano , Adulto , Biomarcadores/sangre , Inhibidor Tisular de Metaloproteinasa-1/sangre , Inhibidor Tisular de Metaloproteinasa-1/genética , Metaloproteinasa 9 de la Matriz/sangre , Metaloproteinasa 9 de la Matriz/genética , Índice de Severidad de la Enfermedad , Estudios de Casos y Controles , Peptidil-Dipeptidasa A/sangre , Peptidil-Dipeptidasa A/genética
2.
J Pediatr ; 209: 125-129, 2019 06.
Artículo en Inglés | MEDLINE | ID: mdl-30952507

RESUMEN

OBJECTIVES: To evaluate the impact of the American Academy of Pediatrics revised recommendations (2014) for palivizumab prophylaxis on respiratory syncytial virus (RSV) admissions and severity of illness among children ≥29 weeks and <35 weeks of gestational age. STUDY DESIGN: We evaluated patients hospitalized with RSV infection from October 1, 2012, through April 30, 2017. RSV hospitalizations, community RSV activity, duration of hospitalization, disease severity, and mortality were reviewed. Data were compared before and after implementation of the guideline changes. RESULTS: A total of 91 patients were born at ≥29 weeks and <35 weeks of gestational age and hospitalized within the first year of life during the evaluation period. Gestational age, birth weight, age at diagnosis, and sex remained constant over the seasons evaluated. RSV hospitalizations and activity in the community were unchanged over 5 years. Duration of hospitalization increased. There was no difference in need for intensive care, supplemental oxygen, or mechanical ventilation or mortality. CONCLUSIONS: Implementation of the 2014 American Academy of Pediatrics guidelines regarding eligibility for palivizumab prophylaxis in older infants born preterm did not increase RSV hospitalizations or disease severity among children hospitalized for RSV at our hospital. Our data support continued adherence to the guidelines.


Asunto(s)
Antivirales/uso terapéutico , Palivizumab/uso terapéutico , Guías de Práctica Clínica como Asunto , Infecciones por Virus Sincitial Respiratorio/prevención & control , Academias e Institutos , Femenino , Edad Gestacional , Humanos , Lactante , Recién Nacido , Masculino , Admisión del Paciente/estadística & datos numéricos , Pediatría , Estudios Retrospectivos , Índice de Severidad de la Enfermedad
3.
MMWR Recomm Rep ; 64(RR-02): 1-26, 2015 Feb 20.
Artículo en Inglés | MEDLINE | ID: mdl-25695372

RESUMEN

This report outlines recommendations for the clinical use of the three smallpox vaccines stored in the U.S. Strategic National Stockpile for persons who are exposed to smallpox virus or at high risk for smallpox infection during a postevent vaccination program following an intentional or accidental release of the virus. No absolute contraindications exist for smallpox vaccination in a postevent setting. However, several relative contraindications exist among persons with certain medical conditions. CDC recommendations for smallpox vaccine use were developed in consideration of the risk for smallpox infection, risk for an adverse event following vaccination, and benefit from vaccination. Smallpox vaccines are made from live vaccinia viruses that protect against smallpox disease. They do not contain variola virus, the causative agent of smallpox. The three smallpox vaccines stockpiled are ACAM2000, Aventis Pasteur Smallpox Vaccine (APSV), and Imvamune. Surveillance and containment activities including vaccination with replication-competent smallpox vaccine (i.e., vaccine viruses capable of replicating in mammalian cells such as ACAM2000 and APSV) will be the primary response strategy for achieving epidemic control. Persons exposed to smallpox virus are at high risk for developing and transmitting smallpox and should be vaccinated with a replication-competent smallpox vaccine unless severely immunodeficient. Because of a high likelihood of a poor immune response and an increased risk for adverse events, smallpox vaccination should be avoided in persons with severe immunodeficiency who are not expected to benefit from vaccine, including bone marrow transplant recipients within 4 months of transplantation, persons infected with HIV with CD4 cell counts <50 cells/mm3, and persons with severe combined immunodeficiency, complete DiGeorge syndrome, and other severely immunocompromised states requiring isolation. If antivirals are not immediately available, it is reasonable to consider the use of Imvamune in the setting of a smallpox virus exposure in persons with severe immunodeficiency. Persons without a known smallpox virus exposure might still be at high risk for developing smallpox infection depending on the magnitude of the outbreak and the effectiveness of the public health response. Such persons will be defined by public health authorities and should be screened for relative contraindications to smallpox vaccination. Relative contraindications include atopic dermatitis (eczema), HIV infection (CD4 cell counts of 50-199 cells/mm3), other immunocompromised states, and vaccine or vaccine-component allergies. Persons with relative contraindications should be vaccinated with Imvamune when available and authorized for use by the Food and Drug Administration. These recommendations will be updated as new data on smallpox vaccines become available and further clinical guidance for other medical countermeasures including antivirals is developed.


Asunto(s)
Programas de Inmunización/normas , Guías de Práctica Clínica como Asunto , Vacuna contra Viruela/administración & dosificación , Viruela/prevención & control , Derrame de Material Biológico , Bioterrorismo , Planificación en Desastres , Humanos , Estados Unidos
4.
J Pediatr ; 212: 247-248, 2019 09.
Artículo en Inglés | MEDLINE | ID: mdl-31204023
5.
J Proteome Res ; 12(1): 481-90, 2013 Jan 04.
Artículo en Inglés | MEDLINE | ID: mdl-23163834

RESUMEN

Rabies is a rapidly progressive lyssavirus encephalitis that is statistically 100% fatal. There are no clinically effective antiviral drugs for rabies. An immunologically naïve teenager survived rabies in 2004 through improvised supportive care; since then, 5 additional survivors have been associated with use of the so-called Milwaukee Protocol (MP). The MP applies critical care focused on the altered metabolic and physiologic states associated with rabies. The aim of this study was to examine the metabolic profile of cerebrospinal fluid (CSF) from rabies patients during clinical progression of rabies encephalitis in survivors and nonsurvivors and to compare these samples with control CSF samples. Unsupervised clustering algorithms distinguished three stages of rabies disease and identified several metabolites that differentiated rabies survivors from those who subsequently died, in particular, metabolites related to energy metabolism and cell volume control. Moreover, for those patients who survived, the trajectory of their metabolic profile tracked toward the control profile and away from the rabies profile. NMR metabolomics of human rabies CSF provide new insights into the mechanisms of rabies pathogenesis, which may guide future therapy of this disease.


Asunto(s)
Metabolómica , Virus de la Rabia , Rabia , Adolescente , Adulto , Antivirales/líquido cefalorraquídeo , Antivirales/inmunología , Femenino , Perfilación de la Expresión Génica , Humanos , Masculino , Rabia/líquido cefalorraquídeo , Rabia/tratamiento farmacológico , Rabia/inmunología , Rabia/metabolismo , Rabia/patología , Vacunas Antirrábicas/líquido cefalorraquídeo , Vacunas Antirrábicas/inmunología , Vacunas Antirrábicas/metabolismo , Vacunas Antirrábicas/uso terapéutico , Virus de la Rabia/efectos de los fármacos , Virus de la Rabia/inmunología , Virus de la Rabia/patogenicidad
6.
Front Med (Lausanne) ; 10: 982290, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-36844226

RESUMEN

Background: Rabies is a highly fatal disease. Once symptoms develop, death usually occurs within days. Survivors were occasionally reported in the literatures. Ante-mortem diagnosis remains a challenge in most rabies endemic countries. A novel, accurate diagnostic assay is highly desirable. Methods: We used metagenomic next-generation sequencing (mNGS) to examine the cerebrospinal fluid (CSF) samples of a 49-year-old patient with rabies and validated the results by TaqMan PCR and RT-PCR/Sanger sequencing. Results: Metagenomic next-generation sequencing identified sequence reads uniquely aligned to the rabies virus (RABV). PCR confirmed the presence of the partial RABV N gene in the CSF. Phylogenetic analysis showed that the RABV grouped as an Asian clade, which is the most broadly distributed clade in China. Conclusion: Metagenomic next-generation sequencing may be a useful screening tool for the etiological diagnosis of rabies, especially in the absence of timely rabies laboratory testing or in patients with no exposure history.

7.
J Am Heart Assoc ; 12(4): e027990, 2023 02 21.
Artículo en Inglés | MEDLINE | ID: mdl-36789856

RESUMEN

Background Cardiac fibrosis complicates SARS-CoV-2 infections and has been linked to arrhythmic complications in survivors. Accordingly, we sought evidence of increased HSP47 (heat shock protein 47), a stress-inducible chaperone protein that regulates biosynthesis and secretion of procollagen in heart tissue, with the goal of elucidating molecular mechanisms underlying cardiac fibrosis in subjects with this viral infection. Methods and Results Using human autopsy tissue, immunofluorescence, and immunohistochemistry, we quantified Hsp47+ cells and collagen α 1(l) in hearts from people with SARS-CoV-2 infections. Because macrophages are also linked to inflammation, we measured CD163+ cells in the same tissues. We observed irregular groups of spindle-shaped HSP47+ and CD163+ cells as well as increased collagen α 1(I) deposition, each proximate to one another in "hot spots" of ≈40% of hearts after SARS-CoV-2 infection (HSP47+ P<0.05 versus nonfibrotics and P<0.001 versus controls). Because HSP47+ cells are consistent with myofibroblasts, subjects with hot spots are termed "profibrotic." The remaining 60% of subjects dying with COVID-19 without hot spots are referred to as "nonfibrotic." No control subject exhibited hot spots. Conclusions Colocalization of myofibroblasts, M2(CD163+) macrophages, and collagen α 1(l) may be the first evidence of a COVID-19-related "profibrotic phenotype" in human hearts in situ. The potential public health and diagnostic implications of these observations require follow-up to further define mechanisms of viral-mediated cardiac fibrosis.


Asunto(s)
COVID-19 , Miofibroblastos , Humanos , Miofibroblastos/metabolismo , SARS-CoV-2 , Colágeno/metabolismo , Proteínas de Choque Térmico/metabolismo , Colágeno Tipo I/metabolismo , Fenotipo , Macrófagos/metabolismo , Fibrosis
8.
J Am Vet Med Assoc ; 261(4): 592-596, 2022 12 07.
Artículo en Inglés | MEDLINE | ID: mdl-36476414

RESUMEN

Rabies is the deadliest viral infection known, with no reliable treatment, and although it is entirely preventable, rabies continues to kill more than 60,000 people every year, mostly children in countries where dog rabies is endemic. America is only 1 generation away from the time when rabies killed more than 10,000 animals and 50 Americans every year, but 3 to 5 Americans continue to die annually from rabies. Distressingly, > 50,000 Americans undergo rabies prevention therapy every year after exposure to potentially rabid animals. While enormous progress has been made, more must be done to defeat this ancient but persistent, fatal zoonosis. In the US, lack of public awareness and ambivalence are the greatest dangers imposed by rabies, resulting in unnecessary exposures, anxiety, and risk. Veterinarians have a special role in informing and reassuring the public about prevention and protection from rabies. This summary of current facts and future advances about rabies will assist veterinarians in informing their clients about the disease.


Asunto(s)
Enfermedades de los Perros , Vacunas Antirrábicas , Rabia , Veterinarios , Animales , Perros , Humanos , Rabia/epidemiología , Rabia/prevención & control , Rabia/veterinaria , Zoonosis , Ansiedad , Trastornos de Ansiedad , Vacunas Antirrábicas/uso terapéutico , Enfermedades de los Perros/prevención & control , Enfermedades de los Perros/epidemiología
9.
Clin Infect Dis ; 53(6): 572-4, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21865193

RESUMEN

Rabies has the highest case-fatality rate of all infectious diseases, with 50,000 cases occurring annually worldwide. In 2004 an unvaccinated adolescent survived after novel therapy. We report the management of a child with rabies. Although the implementation of this same therapeutic protocol was successful, the child died after 1 month of hospitalization.


Asunto(s)
Rabia/terapia , Niño , Protocolos Clínicos , Resultado Fatal , Humanos , Masculino , Insuficiencia del Tratamiento
10.
Pediatr Emerg Care ; 27(9): 804-7, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21878831

RESUMEN

STUDY OBJECTIVE: The 2009 H1N1 pandemic (H1N1pdm) virus has been associated with high rates of asymptomatic infections. Existing influenza infection control policies do not address potential transmission through exposure to asymptomatic infected individuals in health care settings. We conducted a seroprevalence study of H1N1pdm infection to determine whether health care workers (HCWs) in the emergency department showed increased evidence of infection during the first wave of the pandemic than that previously reported in adults in the community. METHODS: Blood samples and demographic and clinical data were collected from eligible emergency department HCWs. Subjects' sera were tested for presence of antibodies specific for seasonal H1N1 and H1N1pdm viruses by hemagglutination-inhibition assay. RESULTS: One hundred eight subjects were enrolled, of which 20 (18.5%) were seropositive for H1N1pdm and 52 (48%) for seasonal H1N1. The median age of H1N1pdm-seropositive subjects was 32 years (range, 24-59 years). Of H1N1pdm-seropositive subjects, 35% were asymptomatic. Rates of H1N1pdm detection in HCWs (18.5%) were significantly higher than those observed previously in an identical age cohort in the community (2.6%, n = 262). CONCLUSIONS: The higher serodetection rates in adults observed in the current study suggest potentially significantly more frequent infections in HCWs than in the general population. Further investigations are needed to ascertain the relative incidence of influenza infections in HCWs and non-HCWs, to study influenza transmission by asymptomatic infected subjects and ascertain the burden of such transmission in health care settings.


Asunto(s)
Anticuerpos Antivirales/sangre , Antígenos Virales/inmunología , Servicio de Urgencia en Hospital/estadística & datos numéricos , Glicoproteínas Hemaglutininas del Virus de la Influenza/inmunología , Transmisión de Enfermedad Infecciosa de Paciente a Profesional/estadística & datos numéricos , Subtipo H1N1 del Virus de la Influenza A/inmunología , Gripe Humana/epidemiología , Enfermedades Profesionales/epidemiología , Pandemias/estadística & datos numéricos , Personal de Hospital/estadística & datos numéricos , Adolescente , Adulto , Anciano , Enfermedades Asintomáticas , Infección Hospitalaria/epidemiología , Exposición a Riesgos Ambientales , Femenino , Hospitales Pediátricos/estadística & datos numéricos , Hospitales Privados/estadística & datos numéricos , Humanos , Subtipo H1N1 del Virus de la Influenza A/clasificación , Vacunas contra la Influenza , Gripe Humana/sangre , Gripe Humana/transmisión , Gripe Humana/virología , Masculino , Persona de Mediana Edad , Enfermedades Profesionales/sangre , Enfermedades Profesionales/virología , Estudios Seroepidemiológicos , Wisconsin/epidemiología , Adulto Joven
11.
Pediatr Infect Dis J ; 40(9): 802-807, 2021 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-33990518

RESUMEN

BACKGROUND: Blastomycosis, an endemic mycosis of immunocompetent individuals, is typically seen after exposure to waterways within rural wooded regions. It is not considered a disease of urban environments. Infection can be solely pneumonic or disseminate to skin, bone or central nervous system. Unknown factors influence disease acquisition and severity in children. METHODS: We analyzed acquisition risks and disease characteristics of blastomycosis in children seen at a tertiary care center from 1998 to 2018 to identify potential exposure sources, measure disease severity and assess the effect of race upon disease severity. RESULTS: Of 64 infected children, mean age was 12.9 years, with median time to diagnosis 38.5 days. About 72% were male, 38% resided in urban counties and 50% had typical environmental exposure. Isolated pulmonary infection occurred in 33 (52%). The remainder had evidence of dissemination to skin (N = 13), bone (N = 16; 7 clinically silent) and cranium (N = 7; 3 clinically silent). Infection was moderate/severe in 19 (30%). Two children (3%) died. About 79% of children with moderate/severe disease (P = 0.008) and 71% of urban children (P = 0.007) lacked typical environmental exposure. Comparing children from urban counties to other residences, 63% versus 5% were black (P < 0.001) and 71% versus 35% developed extrapulmonary dissemination (P = 0.006). Moderate/severe disease was seen in 7/17 (42%) black children but only 12/47 (26%) children of other races (P = 0.23). CONCLUSIONS: Blastomycosis, can be endemic in urban children in the absence of typical exposure history, have frequent, sometimes clinically silent, extrapulmonary dissemination and possibly produces more severe disease in black children.


Asunto(s)
Blastomyces/genética , Blastomicosis/microbiología , Gravedad del Paciente , Población Urbana/estadística & datos numéricos , Adolescente , Negro o Afroamericano/estadística & datos numéricos , Blastomyces/aislamiento & purificación , Blastomicosis/diagnóstico , Blastomicosis/etnología , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Estudios Retrospectivos , Factores de Riesgo , Centros de Atención Terciaria/estadística & datos numéricos , Wisconsin
12.
N Engl J Med ; 352(24): 2508-14, 2005 Jun 16.
Artículo en Inglés | MEDLINE | ID: mdl-15958806

RESUMEN

We report the survival of a 15-year-old girl in whom clinical rabies developed one month after she was bitten by a bat. Treatment included induction of coma while a native immune response matured; rabies vaccine was not administered. The patient was treated with ketamine, midazolam, ribavirin, and amantadine. Probable drug-related toxic effects included hemolysis, pancreatitis, acidosis, and hepatotoxicity. Lumbar puncture after eight days showed an increased level of rabies antibody, and sedation was tapered. Paresis and sensory denervation then resolved. The patient was removed from isolation after 31 days and discharged to her home after 76 days. At nearly five months after her initial hospitalization, she was alert and communicative, but with choreoathetosis, dysarthria, and an unsteady gait.


Asunto(s)
Anestésicos/uso terapéutico , Antivirales/uso terapéutico , Coma/inducido químicamente , Ketamina/uso terapéutico , Virus de la Rabia/inmunología , Rabia/tratamiento farmacológico , Adolescente , Amantadina/uso terapéutico , Animales , Atetosis/etiología , Benzodiazepinas/uso terapéutico , Mordeduras y Picaduras , Quirópteros , Corea/etiología , Disartria/etiología , Femenino , Trastornos Neurológicos de la Marcha/etiología , Humanos , Midazolam/uso terapéutico , Rabia/terapia , Ribavirina/uso terapéutico
13.
PLoS Negl Trop Dis ; 12(12): e0007045, 2018 12.
Artículo en Inglés | MEDLINE | ID: mdl-30557317

RESUMEN

BACKGROUND: Myriad infectious and noninfectious causes of encephalomyelitis (EM) have similar clinical manifestations, presenting serious challenges to diagnosis and treatment. Metabolomics of cerebrospinal fluid (CSF) was explored as a method of differentiating among neurological diseases causing EM using a single CSF sample. METHODOLOGY/PRINCIPAL FINDINGS: 1H NMR metabolomics was applied to CSF samples from 27 patients with a laboratory-confirmed disease, including Lyme disease or West Nile Virus meningoencephalitis, multiple sclerosis, rabies, or Histoplasma meningitis, and 25 controls. Cluster analyses distinguished samples by infection status and moderately by pathogen, with shared and differentiating metabolite patterns observed among diseases. CART analysis predicted infection status with 100% sensitivity and 93% specificity. CONCLUSIONS/SIGNIFICANCE: These preliminary results suggest the potential utility of CSF metabolomics as a rapid screening test to enhance diagnostic accuracies and improve patient outcomes.


Asunto(s)
Enfermedades del Sistema Nervioso Central/líquido cefalorraquídeo , Líquido Cefalorraquídeo/química , Espectroscopía de Resonancia Magnética/métodos , Metabolómica/métodos , Adolescente , Sistema Nervioso Central/inmunología , Enfermedades del Sistema Nervioso Central/diagnóstico , Enfermedades del Sistema Nervioso Central/inmunología , Niño , Preescolar , Femenino , Humanos , Masculino , Adulto Joven
14.
J Pediatr Genet ; 6(2): 61-76, 2017 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-28496993

RESUMEN

A pilot program was initiated using whole genome sequencing (WGS) to diagnose suspected genetic disorders in the Genetics Clinic at Children's Hospital of Wisconsin. Twenty-two patients underwent WGS between 2010 and 2013. Initially, we obtained a 14% (3/22) diagnosis rate over 2 years; with subsequent reanalysis, this increased to 36% (8/22). Disease causing variants were identified in SKIV2L, CECR1, DGKE, PYCR2, RYR1, PDGFRB, EFTUD2, and BCS1L. In 75% (6/8) of diagnosed cases, the diagnosis affected treatment and/or medical surveillance. Additionally, one case demonstrated a homozygous A18V variant in VLDLR that appears to be associated with a previously undescribed phenotype.

15.
Ann Clin Microbiol Antimicrob ; 5: 21, 2006 Sep 08.
Artículo en Inglés | MEDLINE | ID: mdl-16961922

RESUMEN

BACKGROUND: Traumatic injuries occurring in agricultural settings are often associated with infections caused by unusual organisms. Such agents may be difficult to isolate, identify, and treat effectively. CASE REPORT: A 4-year-old boy developed an extensive infection of his knee and distal femur following a barnyard pitchfork injury. Ultimately the primary infecting agent was determined to be Myceliophthora thermophila, a thermophilic melanized hyphomycete, rarely associated with human infection, found in animal excreta. Because of resistance to standard antifungal agents including amphotericin B and caspofungin, therapy was instituted with a prolonged course of terbinafine and voriconazole. Voriconazole blood levels demonstrated that the patient required a drug dosage (13.4 mg/kg) several fold greater than that recommended for adults in order to attain therapeutic blood levels. CONCLUSION: Unusual pathogens should be sought following traumatic farm injuries. Pharmacokinetic studies may be of critical importance when utilizing antifungal therapy with agents for which little information exists regarding drug metabolism in children.


Asunto(s)
Traumatismos de la Rodilla/complicaciones , Hongos Mitospóricos/aislamiento & purificación , Micosis/etiología , Osteomielitis/etiología , Preescolar , Humanos , Masculino , Pirimidinas/uso terapéutico , Triazoles/uso terapéutico , Voriconazol
16.
Am J Health Syst Pharm ; 73(6): 405-8, 2016 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-26953285

RESUMEN

PURPOSE: One hospital's implementation of revised American Academy of Pediatrics (AAP) guidelines for palivizumab prophylaxis of respiratory syncytial virus (RSV) infection is described. METHODS: Revised AAP guidelines for RSV prophylaxis in infants and young children at increased risk for RSV infection recommend that up to five doses of palivizumab be administered during the RSV season. The guidelines also recommend that inpatients not receive monthly palivizumab prophylaxis and that infants and young children eligible for prophylaxis during the RSV season receive a dose of palivizumab two or three days before discharge or promptly after discharge. To ensure compliance with the revised AAP guidelines, a 296-bed hospital implemented a quality-improvement project including (1) efforts by the antimicrobial stewardship pharmacist and the chief medical officer to notify and educate healthcare providers regarding institutional adoption of the guidelines, (2) reinforcement of guideline adherence by clinical pharmacists during daily bedside rounds and via prospective review of all palivizumab orders, and (3) a medication-use evaluation (MUE) to assess adherence to the guidelines. The MUE results showed that during the 2014-15 RSV season (after implementation of the practice changes), the number of palivizumab doses administered at the hospital declined by 56% from the previous RSV season, with 97% of doses administered for appropriate indications. CONCLUSION: Standardized, comprehensive guidelines with defined criteria for palivizumab prophylaxis of RSV infection resulted in $303,227 of cost savings without a discernible change in nosocomial transmission, or morbidity, or mortality. Hospital infection-control practices controlled nosocomial RSV transmission.


Asunto(s)
Antivirales/uso terapéutico , Hospitales Pediátricos/normas , Palivizumab/uso terapéutico , Pediatría/normas , Guías de Práctica Clínica como Asunto/normas , Profilaxis Pre-Exposición/normas , Antivirales/economía , Niño , Preescolar , Infección Hospitalaria/tratamiento farmacológico , Infección Hospitalaria/economía , Hospitales Pediátricos/economía , Humanos , Lactante , Recién Nacido , Palivizumab/economía , Pediatría/educación , Profilaxis Pre-Exposición/economía , Infecciones por Virus Sincitial Respiratorio/economía , Infecciones por Virus Sincitial Respiratorio/prevención & control , Sociedades Médicas/normas , Estados Unidos/epidemiología
18.
Pediatr Infect Dis J ; 24(12): 1109-10, 2005 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-16371876

RESUMEN

Rabies has become a disease of increasing concern. One reason is that bat variant rabies is a more common cause of human disease, with 1-2 deaths per year in the United States. Bat bites are much more difficult to document than bites from larger animals. Deaths from rabies encephalitis have remained undiagnosed until postmortem examination. Prophylaxis includes a series of 5 vaccinations during 28 days. Vaccine efficacy has been documented, even in young children.


Asunto(s)
Quirópteros/virología , Vacunas Antirrábicas/administración & dosificación , Virus de la Rabia/inmunología , Rabia/prevención & control , Animales , Anticuerpos Antivirales/sangre , Mordeduras y Picaduras , Niño , Preescolar , Humanos , Lactante , Masculino , Rabia/inmunología , Rabia/virología , Vacunas Antirrábicas/inmunología , Vacunación
19.
Infect Dis Clin North Am ; 29(4): 637-50, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26384549

RESUMEN

Rabies is an acute, rapidly progressive encephalitis that is almost always fatal. Prophylaxis is highly effective but economics limits disease control. The mechanism of death from rabies is unclear. It is poorly cytopathic and poorly inflammatory. Rabies behaves like an acquired metabolic disorder. There may be a continuum of disease severity. History of animal bite is rare. The diagnosis is often missed. Intermittent encephalopathy, dysphagia, hydrophobia and aerophobia, and focal paresthesias or myoclonic jerks suggest rabies. Laboratory diagnosis is cumbersome but sensitive. Treatment is controversial but survivors are increasingly reported, with good outcomes in 4 of 8 survivors.


Asunto(s)
Vacunas Antirrábicas/administración & dosificación , Rabia/epidemiología , Rabia/terapia , Enfermedades Raras/epidemiología , Enfermedades Raras/terapia , Animales , Mordeduras y Picaduras/virología , Humanos , Profilaxis Pre-Exposición , Rabia/prevención & control , Virus de la Rabia/patogenicidad , Enfermedades Raras/prevención & control
20.
Pediatrics ; 136(1): e242-5, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-26055849

RESUMEN

Diphtheria is a rare cause of infection in highly vaccinated populations and may not be recognized by modern clinicians. Infections by nontoxigenic Corynebacterium diphtheriae are emerging. We report the first case of necrotizing epiglottitis secondary to nontoxigenic C diphtheriae. A fully vaccinated child developed fever, poor oral intake, and sore throat and was found to have necrotizing epiglottitis. Necrotizing epiglottitis predominantly occurs in the immunocompromised host. Laboratory evaluation revealed pancytopenia, and bone marrow biopsy was diagnostic for acute lymphoblastic leukemia. Clinicians should be aware of aggressive infections that identify immunocompromised patients. This case highlights the features of a reemerging pathogen, C diphtheriae.


Asunto(s)
Infecciones por Corynebacterium/microbiología , Corynebacterium diphtheriae/aislamiento & purificación , Epiglotitis/microbiología , Preescolar , Infecciones por Corynebacterium/diagnóstico , Epiglotitis/diagnóstico , Femenino , Humanos , Huésped Inmunocomprometido , Pruebas de Sensibilidad Microbiana , Necrosis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA